These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2139702)

  • 21. Treatment of metastatic prostate carcinoma with the depot LRH analog Zoladex.
    Holdaway IM; Ibbertson HK; Croxson MS; Harvey V; Boulton J; List A; Rutland M; Knox BS
    Prostate; 1988; 12(2):119-27. PubMed ID: 2966931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined treatment (goserelin plus flutamide) versus monotherapy (goserelin alone) in advanced prostate cancer: a randomized study.
    Jurincic CD; Horlbeck R; Klippel KF
    Semin Oncol; 1991 Oct; 18(5 Suppl 6):21-5. PubMed ID: 1835139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
    Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
    Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
    [No Abstract]   [Full Text] [Related]  

  • 25. [Zoladex in prostatic carcinoma].
    Di Silverio F; Serio M
    Drugs Exp Clin Res; 1990; 16 Suppl():19-29. PubMed ID: 2150501
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical efficacy of long-term treatment with LH-RH analogue, ICI 118630 (Zoladex), in prostatic cancer patients. The Zoladex Multicenter Study Group].
    Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Akaza H; Nihsijima T; Aso Y; Araki T; Itatani H
    Hinyokika Kiyo; 1988 Nov; 34(11):2059-66. PubMed ID: 2977261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter trial comparing the luteinizing hormone releasing hormone analog Zoladex, with Zoladex plus flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.
    Lunglmayr G
    Eur Urol; 1990; 18 Suppl 3():28-9. PubMed ID: 2151273
    [No Abstract]   [Full Text] [Related]  

  • 28. A new hormonal therapy for prostatic cancer: long-term clinical and hormonal response.
    Ahmed SR; Grant JB; Shalet SM; Howell A; Costello CB; Weatherson T; Blacklock NJ
    Br J Urol; 1986 Oct; 58(5):534-8. PubMed ID: 2946355
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic factors of advanced prostatic carcinoma.
    Lukkarinen O; Lehikoinen K
    Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of buserelin in advanced prostate cancer and comparison with historical controls.
    Soloway MS
    Am J Clin Oncol; 1988; 11 Suppl 1():S29-32. PubMed ID: 3133944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical study of an LH-RH agonist (ICI 118.630, Zoladex) in the treatment of prostatic cancer.
    Mauriac L; Coste P; Richaud P; Lamarche P; Mage P; Bonichon F
    Am J Clin Oncol; 1988; 11 Suppl 2():S117-9. PubMed ID: 2977265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial.
    Zinner NR; Bidair M; Centeno A; Tomera K
    Urology; 2004 Dec; 64(6):1177-81. PubMed ID: 15596193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
    Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
    BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
    Kerle D; Williams G; Ware H; Doble A; Allen J; Bloom SR
    Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of long-acting LHRH analog (Zoladex) on prostate cancer: evaluated by transrectal ultrasonography.
    Drago JR; Nesbitt JA; Cirulli C
    Urology; 1988 Oct; 32(4):285-7. PubMed ID: 2972104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
    Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison between surgical orchidectomy and the LHRH agonist 'Zoladex' (ICI 188630) in the treatment of metastatic cancer of the prostate.
    Peeling WB
    Prog Clin Biol Res; 1989; 303():41-5. PubMed ID: 2528738
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent developments in endocrine treatment of prostate cancer.
    Vogelzang NJ; Kennealey GT
    Cancer; 1992 Aug; 70(4 Suppl):966-76. PubMed ID: 1386283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M; Cavalli V; Bravi F
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.